Insmed Inc (INSM)vsNovaBay Pharmaceuticals Inc (NBY)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
NBY
NovaBay Pharmaceuticals Inc
$1.42
-5.33%
HEALTHCARE · Cap: $30.30M
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 5786% more annual revenue ($606.42M vs $10.30M). NBY leads profitability with a 31.5% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
NBY
Avoid33
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for INSM.
Margin of Safety
+99.6%
Fair Value
$175.44
Current Price
$1.42
$174.02 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Attractively priced relative to earnings
Keeps 32 of every $100 in revenue as profit
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -5.2% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : NBY
The strongest argument for NBY centers on P/E Ratio, Profit Margin. Profitability is solid with margins at 31.5% and operating margin at -2.2%.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : NBY
The primary concerns for NBY are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while NBY is a declining play — different risk/reward profiles.
INSM carries more volatility with a beta of 1.17 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
NBY generates stronger free cash flow (-2M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 33/100). NBY offers better value entry with a 99.6% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
NovaBay Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
NovaBay Pharmaceuticals, Inc., a medical device company, develops products for the eye care markets in the United States and internationally. The company is headquartered in Emeryville, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?